You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameAnti-Met (c-Met) antibody [SP59]See all Met (c-Met) primary antibodies ...
  • Description
    Rabbit monoclonal [SP59] to Met (c-Met)
  • Tested applicationsIHC-P more details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to the region of Human Met (c-Met) that contains non-phosphorylated Tyrosine 1003.

  • Positive controlBreast carcinoma

Properties

Applications

Our Abpromise guarantee covers the use of ab101539 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
IHC-P IHC-P: 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Target

  • FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
  • Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
    Note=Defects in MET may be associated with gastric cancer.
    Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
    Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
    Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
    Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
    Contains 3 IPT/TIG domains.
    Contains 1 protein kinase domain.
    Contains 1 Sema domain.
  • DomainThe kinase domain is involved in SPSB1 binding.
  • Post-translational
    modifications    Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
  • Cellular localizationMembrane.

    • Target information above from: UniProt accession P08581 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
    • Alternative names
        AUTS9 antibodyc met antibodyD249 antibody
        Hepatocyte growth factor receptor antibodyHGF antibodyHGF receptor antibodyHGF/SF receptor antibodyHGFR antibodyMET antibodyMet proto oncogene tyrosine kinase antibodyMet proto-oncogene (hepatocyte growth factor receptor) antibodyMet proto-oncogene antibodyMet protooncogene antibodyMET_HUMAN antibodyOncogene MET antibodyPar4 antibodyProto-oncogene c-Met antibodyRCCP2 antibodyScatter factor receptor antibodySF receptor antibodyTyrosine-protein kinase Met antibody
      see all

    Anti-Met (c-Met) antibody [SP59] images

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Met (c-Met) antibody [SP59] (ab101539)
      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Met (c-Met) antibody [SP59] (ab101539)
      ab101539 at 1/100 dilution staining Met (C-Met) in Human breast carcinoma by Immunohistochemistry Formalin-fixed, Paraffin-embedded tissue.

    References for Anti-Met (c-Met) antibody [SP59] (ab101539)

    ab101539 has not yet been referenced specifically in any publications.

    Publishing research using ab101539 ? Please let us know so that we can cite the reference in this datasheet

    Product Wall

    Submit an Abreview for ab101539 Submit a Question for ab101539

    There are currently no Abreviews or Questions for ab101539.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"